echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > BeiGene Baiyueze® is approved in the EU for the treatment of adult Fahrenheit macroglobulinemia

    BeiGene Baiyueze® is approved in the EU for the treatment of adult Fahrenheit macroglobulinemia

    • Last Update: 2021-12-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 24, BeiGene announced that the European Commission had approved Baiyueze® (Zebutinib) for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM) who had received at least one treatment in the past, or as unsuitable Chemotherapy and immunotherapy are the first-line treatment options for WM patients


    Following the positive opinion of the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP) in September, Beacon® was approved by the European Commission this time based on the results of the ASPEN trial


    Waldenstrom's macroglobulinemia (WM) is a relatively indolent and rare B-cell malignancy, manifested by lymphoplasmic cells secreting monoclonal immunoglobulin M (IgM) invading the bone marrow


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.